The company has a strong lineup of products in development and brings in solid revenue and earnings. It remains focused on innovation, with recent regulatory approvals including Winrevair, a treatment ...

Looking at options history for Merck & Co (NYSE: MRK) we detected 13 trades. If we consider the specifics of each trade, it is accurate to state that 46% of the investors opened trades with bullish ...

Delving into the details, we found 35% of traders were bullish, while 41% showed bearish tendencies. Out of all the trades we spotted, 3 were puts, with a value of $139,802, and 14 were calls, valued ...

We recently compiled a list of the 12 Most Reliable Dividend Stocks To Buy According to Hedge Funds. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against ...

Investors with a lot of money to spend have taken a bullish stance on Merck & Co (NYSE:MRK). And retail traders should know. We noticed this today when the trades showed up on publicly available ...

Merck (MRK) stock achieved a 5-day winning streak, with total gains during this time reaching 6.9%. The company’s market ...

Merck & Co Inc (Symbol: MRK) has been named a Top Socially Responsible Dividend Stock by Dividend Channel, signifying a stock with above-average ''DividendRank'' statistics including a strong 4.2% ...

Merck (MRK) ended the recent trading session at $99.01, demonstrating a +1.42% change from the preceding day's closing price. The stock outpaced the S&P 500's daily gain of 0.21%. On the other hand, ...

Merck & Co.'s peptides could be undergoing a transformation into oral tablets thanks to a $493 million licensing deal the company inked with Austria-based drug delivery technology maker Cyprumed.